Greenland Mines Ltd (NASDAQ: GRML) announced that IP Australia has granted Australian Patent No. 2023252508, which covers gene therapy technology exclusively licensed by the company’s Biotech Division for the treatment of neuromuscular diseases through expression of the human Klotho protein. The patent strengthens the intellectual property supporting Greenland Mines’ Klotho-based therapeutic platform and includes claims covering gene therapy constructs, neuronal and induced pluripotent stem cells, and viral and non-viral delivery systems.
The company said the patent further supports development of its KLTO-202 program targeting amyotrophic lateral sclerosis (“ALS”) and other neuromuscular disorders. According to the press release, the patent covers a broad range of technologies central to the company’s gene therapy efforts, including methods for delivering the Klotho gene to target cells. This milestone is significant for Greenland Mines as it expands its patent portfolio beyond the United States and other jurisdictions, providing protection in a key market for biotech innovation.
Greenland Mines Ltd is a Nasdaq-listed company with two operating divisions: (1) Mining, focused on the exploration and development of the Skaergaard Project in southeast Greenland and, subject to closing of the previously announced transaction, the Sarfartoq neodymium-praseodymium (Nd-Pr) rare earths project in southwest Greenland; and (2) Biotech, including Klotho’s KLTO-202 primary indication for ALS. The company’s strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals and selected midstream processing opportunities, while advancing its broader North Atlantic Critical Metals Corridor vision linking Greenland resources with allied downstream jurisdictions and industrial infrastructure.
The granting of this Australian patent underscores the potential of the Klotho gene therapy platform to address serious neuromuscular conditions. ALS, a progressive neurodegenerative disease, currently has limited treatment options, and gene therapy approaches like KLTO-202 aim to modify disease progression by increasing Klotho protein levels, which have been linked to neuroprotection. For further details, the full press release is available at https://nnw.fm/PVbbH.
Investors can find the latest news and updates relating to GRML in the company’s newsroom at https://nnw.fm/GRML.
